Arrowhead Pharmaceuticals(ARWR)
$49.36+0.36 (+0.73%)
ARWR
Arrowhead Pharmaceuticals stock forecast
$49.36
At close:+0.36 (+0.73%)
Want to see ARWR full AI Analyst Report?
Arrowhead Pharmaceuticals (ARWR) Stock Forecast & Price Target
1,735 Followers
ARWR Analyst Ratings
Strong Buy
11Buy1Hold0Sell
Based on 12 analysts giving stock ratings to Arrowhead Pharmaceuticals in the past 3 months
ARWR Stock 12 Month Forecast
Average Price Target
$108.40▲(119.61% Upside)Based on 12 Wall Street analysts offering 12 month price targets for Arrowhead Pharmaceuticals in the last 3 months. The average price target is $108.40 with a high forecast of $126.00 and a low forecast of $74.00. The average price target represents a 119.61% change from the last price of $49.36.
Past 12 Months12 Month ForecastJan2026Oct2026
High$126.00
Average$108.40
Low$74.00
Highest Price TargetHighest$126.00Average Price Target$108.40Lowest Price TargetLowest$74.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Patrick Trucchio | H.C. Wainwright | $120 | buy | 143.11%Upside | Reiterated | 11/11/26 | ||
| Edward Tenthoff | Piper Sandler | $126 | buy | 155.27%Upside | Reiterated | 11/10/26 | ||
| Madison Elsaadi | B. Riley Securities | $123 | buy | 149.19%Upside | Reiterated | 11/10/26 | ||
 Unknown AnalystNot Ranked | UBS | $109 | buy | 120.83%Upside | Initiated | 10/20/26 | ||
| Brian Cheng | J.P. Morgan | ― | buy | ― | Reiterated | 10/15/26 | ||
| Eric Joseph | Citi | $108 | buy | 118.80%Upside | Reiterated | 10/14/26 | ||
| Jason Gerberry | Bank of America Securities | $100 | buy | 102.59%Upside | Reiterated | 10/12/26 | ||
| Andrea Newkirk | Goldman Sachs | $74 | hold | 49.92%Upside | Initiated | 09/24/26 | ||
| James Condulis | Stifel Nicolaus | $104 | buy | 110.70%Upside | Reiterated | 08/31/26 | ||
| Michael Ulz | Morgan Stanley | $120 | buy | 143.11%Upside | Reiterated | 08/31/26 | ||
| Joseph Thome | TD Cowen | ― | buy | ― | Reiterated | 08/30/26 | ||
| Luca Issi | RBC Capital | $100 | buy | 102.59%Upside | Reiterated | 08/30/26 | ||
| Keay Nakae | Chardan Capital | $115 | buy | 132.98%Upside | Reiterated | 08/04/26 | ||
| William Pickering | Bernstein | $35→$46 | hold | -6.81%Downside | Assigned | 05/13/26 | ||
| Mani Foroohar | Leerink Partners | ― | hold | ― | Reiterated | 03/26/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Patrick TrucchioH.C. Wainwright | BuyReiterated$120 | 11/11/26 | 143.11%Upside | ||
| Edward TenthoffPiper Sandler | BuyReiterated$126 | 11/10/26 | 155.27%Upside | ||
| Madison ElsaadiB. Riley Securities | BuyReiterated$123 | 11/10/26 | 149.19%Upside | ||
| Unknown AnalystUBSNot Ranked | BuyInitiated$109 | 10/20/26 | 120.83%Upside | ||
| Brian ChengJ.P. Morgan | BuyReiterated | 10/15/26 | ― | ||
| Eric JosephCiti | BuyReiterated$108 | 10/14/26 | 118.80%Upside | ||
| Jason GerberryBank of America Securities | BuyReiterated$100 | 10/12/26 | 102.59%Upside | ||
| Andrea NewkirkGoldman Sachs | HoldInitiated$74 | 09/24/26 | 49.92%Upside | ||
| James CondulisStifel Nicolaus | BuyReiterated$104 | 08/31/26 | 110.70%Upside | ||
| Michael UlzMorgan Stanley | BuyReiterated$120 | 08/31/26 | 143.11%Upside | ||
| Joseph ThomeTD Cowen | BuyReiterated | 08/30/26 | ― | ||
| Luca IssiRBC Capital | BuyReiterated$100 | 08/30/26 | 102.59%Upside | ||
| Keay NakaeChardan Capital | BuyReiterated$115 | 08/04/26 | 132.98%Upside | ||
| William PickeringBernstein | HoldAssigned$35→$46 | 05/13/26 | -6.81%Downside | ||
| Mani ForooharLeerink Partners | HoldReiterated | 03/26/26 | ― |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Arrowhead Pharmaceuticals
3 Months
Success Rate16/24 ratings generated profit
67%
Average Return
+28.37%
Copying Patrick Trucchio's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +28.37% per trade.
1 Year
Success Rate14/24 ratings generated profit
58%
Average Return
+117.75%
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +117.75% per trade.
2 Years
Success Rate14/21 ratings generated profit
67%
Average Return
+102.61%
Copying Jason Gerberry's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +102.61% per trade.
ARWR Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 1 | 7 | 11 |
| Buy | 30 | 35 | 33 | 20 | 5 |
| Hold | 1 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 32 | 35 | 35 | 28 | 17 |
In the current month, ARWR has received 16 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ARWR average Analyst price target in the past 3 months is 108.40.
ARWR Financial Forecast
High$-0.35
Consensus$-1.52
Low$-3.00
ARWR Earnings Forecast
Next quarter’s earnings estimate for ARWR is -$1.52 with a range of -$3.00 to -$0.35. The previous quarter’s EPS was -$1.36. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$178M
Consensus$61.2M
Low$4.5M
ARWR Sales Forecast
Next quarter’s sales forecast for ARWR is $61.18M with a range of $4.50M to $178.00M. The previous quarter’s sales results were $75.25M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
ARWR Stock Forecast FAQ
What is ARWR’s average 12-month price target, according to analysts?
Based on analyst ratings, Arrowhead Pharmaceuticals’s 12-month average price target is $108.40.
What is ARWR’s upside potential, based on the analysts’ average price target?
Arrowhead Pharmaceuticals has 119.61% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ARWR a Buy, Sell or Hold?
Arrowhead Pharmaceuticals has a consensus rating of Strong Buy which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.
What is Arrowhead Pharmaceuticals’s price target?
The average price target for Arrowhead Pharmaceuticals is $108.40. This is based on 12 12-month price targets, issued in the past 3 months. The highest analyst price target is $126.00, the lowest forecast is $74.00. The average price target represents a 119.61% increase from the current price of $49.36.
What do analysts say about Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Street analysts.
How can I buy shares of ARWR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
